{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-077659","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.218719+00:00","generated_at":"2026-05-17T13:55:14.790954+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem's partner reports 68.8% ORR for VS-7375 in KRAS G12D NSCLC at RP2D","bullets":["ORR of 68.8% (11/16) and DCR of 93.8% (15/16) at recommended Phase 2 dose of 600 mg QD in NSCLC patients.","Across all dose levels, ORR 57.7% (15/26) and DCR 88.5% (23/26) in evaluable advanced NSCLC patients.","Safety profile: TRAEs in 27.5% (39/142), Grade≥3 SAEs in 7.7% (11/142); no TRAE-related deaths; 6 discontinuations.","Data to be presented in mini oral at IASLC WCLC on Sept 7, 2025; builds on prior ASCO ORR of 42% (n=12)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-077659","json":"https://secwatch.observer/filing/0001104659-25-077659.json","markdown":"https://secwatch.observer/filing/0001104659-25-077659.md","text":"https://secwatch.observer/filing/0001104659-25-077659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/0001104659-25-077659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/tm2523452d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:55:14.790954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}